Dozens of drugmakers are conducting human trials for a record 89 therapies that pair antibodies with toxic agents to fight cancer, evidence of renewed confidence in an approach that has long fallen short of its promise, an analysis compiled for Reuters shows. ...
1/6/2020
FibroGen, Inc. (NASDAQ:FGEN), today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for roxadustat for the treatment of anemia of chronic kidney disease (CKD), in both non-dialysis-dependent (NDD) and dialysis-dependent (DD) CKD patients.
12/23/2019
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that CAPLYTA® (lumateperone) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia in adults. The Company expects to initiate the commercial launch of CAPLYTA in late Q1 2020.
12/23/2019
You are here Targeting Alpha-Synuclein in the Gut May Slow Down Parkinson’s Disease 13 November 2019 Scientists are testing the hypothesis that by targeting the gut with a compound that can inhibit the aggregation of alpha-synuclein, they may be able to slow the progression of Parkinson’s disease Amsterdam, NL – Aggregates of the protein alpha-synuclein arising in the gut may ...
11/18/2019
Cibus, a pioneer of precision gene editing for agriculture, has reached significant milestones in developing three new traits for canola, which can increase crop yields for farmers and reduce harmful environmental impacts.
11/6/2019
N. Harris Computer Corporation’s (“Harris”) healthcare group announced today that it has completed the acquisition of Connecture, Inc. (“Connecture”).…
10/7/2019
ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company pioneering the development of highly potent and targeted antibody drug conjugates for patients suffering from hematological malignancies and solid tumors, announced today that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public ...
9/6/2019
A new approach to beating herpes by inducing antibodies that mediate the killing of infected cells -Participants include Johnson & Johnson Innovation – JJDC, Inc. (JJDC); Adjuvant Capital, an impact investment fund supported by the Bill & Melinda Gates Foundation as an anchor investor; Serum Institute of India; Alexandria Venture Investments; Founders Fund. X-Vax Technology NEWS PROVIDED BY X-Vax Technology, ...
7/23/2019
FibroGen, Inc. (NASDAQ: FGEN), today announced that the company will present interim data on their open-label, single-arm…
6/28/2019
FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, today…
6/10/2019
Positive topline results from pooled safety analyses of roxadustat Phase 3 global program Completed one year of treatment in Phase 2 trial evaluating pamrevlumab in…
5/9/2019
MACE/MACE+ endpoints evaluated across CKD patients not on dialysis and on dialysis Superiority in time to first MACE+ versus epoetin alfa in incident dialysis patients…
5/9/2019
FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, today…
4/15/2019
FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, today…
2/27/2019
Connecture, Inc. announces the sales of its Commercial U65 business unit to Benefitfocus With the sale of the U65…
2/26/2019
Crossmatch®, part of HID Global, today announced its fingerprint reading technology is enabling secure identity management on the newly revealed Lenovo ThinkPad T490 Healthcare Edition.…
2/12/2019
